CAR - T cell therapy company Poseida Therapeutics is seeking to raise $ 500 m in an initial public offering ( IPO ) , according to papers filed with securities regulators . Poseida , which is testing CAR - T cell therapies for blood - borne and solid tumour cancers , has filed for a tentative listing under the symbol PSTX . The company wants to use any IPO proceedings to further accelerate clinical development and research of its CAR - T treatment for relapsed / chronic multiple myeloma . It may also set up a pilot manufacturing facility , with an estimated cost of up to $ 15 m , the filing showed .
CAR-T cell therapy company Poseida Therapeutics is seeking to raise $115m in an initial public offering (IPO), according to papers filed with securities regulators. Poseida, which is testing CAR-T cell therapies for blood-borne and solid tumour cancers, has filed for a Nasdaq listing under the symbol PSTX. The company wants to use any IPO proceedings to further fund clinical development and research of its CAR-T treatment for relapsed/refractory multiple myeloma. It may also set up a pilot manufacturing unit, with an estimated cost of up to $15m, the filing showed.